Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVIVO-TaVec400 in Relapsed/Refractory Autoimmune Diseases
NCT07583030Phase 1Withdrawn
- Start
- Sep 2026
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1 trial of LVIVO-TaVec400. Planned start Sep 2026; status: withdrawn.
02
Drugs
LVIVO-TaVec400
Beyond the preview
Go deeper on NCT07583030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583030.